Company intelligence / Profile preview

Anivance AI

Ownership: Private
Development stage: Preclinical

Overview

Anivance AI has developed an advanced platform that combines artificial intelligence with organ-on-chip technology to automate and optimize preclinical drug testing. Their system accelerates experiment design, increases data reliability, reduces failure rates in R&D pipelines, and has been recognized globally for innovation in inhalable nanoparticle delivery and respiratory disease modeling. They collaborate with leading pharmaceutical companies and academic institutions worldwide.

Therapeutic areas: Pulmonology
Modalities: Organ-on-chip modelsInhalable nanoparticle delivery systems
Industry: Drug Discovery Services

Partnerships

Strategic partnerships with top clinical institutions in Taiwan.

Beyond the preview

Go deeper on Anivance AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anivance AI.

Explore the full profile